366 related articles for article (PubMed ID: 28073888)
1. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
Ikenaga N; Peng ZW; Vaid KA; Liu SB; Yoshida S; Sverdlov DY; Mikels-Vigdal A; Smith V; Schuppan D; Popov YV
Gut; 2017 Sep; 66(9):1697-1708. PubMed ID: 28073888
[TBL] [Abstract][Full Text] [Related]
2. LOXL2 Inhibition Paves the Way for Macrophage-Mediated Collagen Degradation in Liver Fibrosis.
Klepfish M; Gross T; Vugman M; Afratis NA; Havusha-Laufer S; Brazowski E; Solomonov I; Varol C; Sagi I
Front Immunol; 2020; 11():480. PubMed ID: 32296422
[TBL] [Abstract][Full Text] [Related]
3. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2.
Vadasz Z; Kessler O; Akiri G; Gengrinovitch S; Kagan HM; Baruch Y; Izhak OB; Neufeld G
J Hepatol; 2005 Sep; 43(3):499-507. PubMed ID: 16023247
[TBL] [Abstract][Full Text] [Related]
4. Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
Pollheimer MJ; Racedo S; Mikels-Vigdal A; Marshall D; Bowlus C; Lackner C; Madl T; Karlsen TH; Hov JR; Lyman SK; Adamkewicz J; Smith V; Moreau E; Zollner G; Eide TJ; Stojakovic T; Scharnagl H; Gruber HJ; Stauber RE; Trauner M; Fickert P
J Hepatol; 2018 Aug; 69(2):368-377. PubMed ID: 29709678
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
6. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.
Yoshida S; Ikenaga N; Liu SB; Peng ZW; Chung J; Sverdlov DY; Miyamoto M; Kim YO; Ogawa S; Arch RH; Schuppan D; Popov Y
Gastroenterology; 2014 Dec; 147(6):1378-92. PubMed ID: 25173753
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway.
Cheng F; Yang F; Wang Y; Zhou J; Qian H; Yan Y
J Nanobiotechnology; 2023 Jun; 21(1):195. PubMed ID: 37328872
[TBL] [Abstract][Full Text] [Related]
8. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
[TBL] [Abstract][Full Text] [Related]
9. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice.
Liu SB; Ikenaga N; Peng ZW; Sverdlov DY; Greenstein A; Smith V; Schuppan D; Popov Y
FASEB J; 2016 Apr; 30(4):1599-609. PubMed ID: 26700732
[TBL] [Abstract][Full Text] [Related]
10. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.
Schilter H; Findlay AD; Perryman L; Yow TT; Moses J; Zahoor A; Turner CI; Deodhar M; Foot JS; Zhou W; Greco A; Joshi A; Rayner B; Townsend S; Buson A; Jarolimek W
J Cell Mol Med; 2019 Mar; 23(3):1759-1770. PubMed ID: 30536539
[TBL] [Abstract][Full Text] [Related]
11. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer.
Ikenaga N; Liu SB; Sverdlov DY; Yoshida S; Nasser I; Ke Q; Kang PM; Popov Y
Am J Pathol; 2015 Feb; 185(2):325-34. PubMed ID: 25478810
[TBL] [Abstract][Full Text] [Related]
12. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction.
An P; Wei G; Huang P; Li W; Qi X; Lin Y; Vaid KA; Wang J; Zhang S; Li Y; Or YS; Jiang LJ; Popov YV
Liver Int; 2020 Jul; 40(7):1655-1669. PubMed ID: 32329946
[TBL] [Abstract][Full Text] [Related]
13. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
[TBL] [Abstract][Full Text] [Related]
14. Significance of nuclear LOXL2 inhibition in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome.
Matsuo A; Tanida R; Yanagi S; Tsubouchi H; Miura A; Shigekusa T; Matsumoto N; Nakazato M
Eur J Pharmacol; 2021 Feb; 892():173754. PubMed ID: 33248114
[TBL] [Abstract][Full Text] [Related]
15. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.
Chen W; Yang A; Jia J; Popov YV; Schuppan D; You H
Hepatology; 2020 Aug; 72(2):729-741. PubMed ID: 32176358
[TBL] [Abstract][Full Text] [Related]
16. LOXL2-A New Target in Antifibrogenic Therapy?
Puente A; Fortea JI; Cabezas J; Arias Loste MT; Iruzubieta P; Llerena S; Huelin P; Fábrega E; Crespo J
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986934
[TBL] [Abstract][Full Text] [Related]
17. Withaferin A reverses bile duct ligation-induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NFκB signaling.
Sayed N; Khurana A; Saifi MA; Singh M; Godugu C
Biofactors; 2019 Nov; 45(6):959-974. PubMed ID: 31336025
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking.
Zhao W; Yang A; Chen W; Wang P; Liu T; Cong M; Xu A; Yan X; Jia J; You H
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1129-1137. PubMed ID: 29366776
[TBL] [Abstract][Full Text] [Related]
19. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies.
Popov Y; Patsenker E; Stickel F; Zaks J; Bhaskar KR; Niedobitek G; Kolb A; Friess H; Schuppan D
J Hepatol; 2008 Mar; 48(3):453-64. PubMed ID: 18221819
[TBL] [Abstract][Full Text] [Related]
20. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
